Diet Drug Acomplia Seen Unlikely to Get FDA Approval for 'Metabolic Syndrome'
If you were hoping that diet drug rimonabant (Acomplia / Zimulti) would be approved for treatment of "metabolic syndrome" so your insurance company would be more likely to pay for your weight-loss efforts, the current thinking at the U.S. Food and Drug Administration does not appear very encouraging.
Read the rest of this entry ... (139 words left)
